ClinicalTrials.gg
RecruitingNCT07575399Updated Nov 6, 2026

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

A Phase 3 interventional study of Maridebart Cafraglutide in Obesity or Overweight, sponsored by Amgen. Recruiting at 57 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 6, 2026Site recruiting status changed13 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Planned enrollment
14th of 28
300 · median 275
Started
2026
with 9 others
Phase 3
11 of 28
6 open now
Primary completion
2028-01
later than 13 of 16 live
Registered
20th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 14th largest by planned enrollment, is one of 10 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 13 of the 16 other live ones, and was the 20th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 25 at screening.
  • Weight loss of ≥ 10% on weekly GLP-1 RA.
  • Stable body weight.
  • Stable dose of GLP-1RA.
  • Stable gastrointestinal (GI) tolerability.
  • for females.
  • Willingness to follow trial procedures for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  • Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
  • Previous or planned surgical, endoscopic or device-based treatment for obesity.
  • History of .
  • Type 1/Type 2 diabetes mellitus (DM).
  • Family or personal history of medullary thyroid cancer.
  • Previous participation in a Maridebart Cafraglutide trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    MariTide Arm 1

    Participants will receive maridebart cafraglutide dosing schedule 1 during the treatment period.

    Drug: Maridebart Cafraglutide

  • Experimental
    MariTide Arm 2

    Participants will receive maridebart cafraglutide dosing schedule 2 during the treatment period.

    Drug: Maridebart Cafraglutide

Interventions

  • Maridebart cafraglutide will be administered via subcutaneous (SC) injection.

    Also known as: AMG 133

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight at Week 68

    Time frame: Week 68

Secondary outcomes

  1. Percent Change in Body Weight Prior to the Start of Weekly GLP-1RA at Week 68

    Time frame: Week 68

  2. Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68

    Time frame: Week 68

  3. Percent Maintenance of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68

    Time frame: Week 68

  4. Plasma Concentration of Maridebart Cafraglutide at Week 68

    Time frame: Week 68

  5. Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events

    Time frame: Up to 84 weeks

07

Study locations

56 of 57 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
May 11, 2026
Primary completionEst.
Jan 3, 2028
CompletionEst.
Feb 28, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 1 site removed. South Texas Research Institute is now Terminated
Show 13 added (13 United States)
  • Clinical Research Institute of Arizona LLC · Sun City West, United States
  • Adult Medicine of Lake County · Mt. Dora, United States
  • East Coast Institute for Research · Canton, United States
  • Mel A. Ona, M.D., Incorporated · Kapolei, United States
  • Central Illinois Diabetes and Clinical Research, a Division of Prairie Education and Research Cooper · Springfield, United States
  • Pinnacle Clinical Research Georgetown · Austin, United States
  • American Research Corporation · San Antonio, United States
  • Gastroenterology Clinic of San Antonio PA · San Antonio, United States
  • Heritage Valley Multispecialty Group Inc · Beaver, United States
  • Peninsula Research Associates · Chula Vista, United States
  • Johnson County Clinical Trials · Lenexa, United States
  • Great Lakes Research Institute · Southfield, United States
  • Biopharma Informatic-McAllen · McAllen, United States
Show 1 removed
  • Peninsula Research Associates · Rolling Hills Estates, United States
across 4 updates, Oct 8, 2026 – Nov 6, 2026
Show all 4 updates
  1. Nov 6, 2026
    3 sites added
    Show 3 added (3 United States)
    • Johnson County Clinical Trials · Lenexa, United States
    • Great Lakes Research Institute · Southfield, United States
    • Biopharma Informatic-McAllen · McAllen, United States
    + 1 other change: verification date
  2. Oct 23, 2026
    1 site added, 1 site removed
    Show site
    • Peninsula Research Associates · Chula Vista, United States
    Show 1 removed
    • Peninsula Research Associates · Rolling Hills Estates, United States
  3. Oct 20, 2026
    1 site added
    Show site
    • Heritage Valley Multispecialty Group Inc · Beaver, United States
  4. Oct 8, 2026
    8 sites added. South Texas Research Institute is now Terminated
    Show 8 added (8 United States)
    • Clinical Research Institute of Arizona LLC · Sun City West, United States
    • Adult Medicine of Lake County · Mt. Dora, United States
    • East Coast Institute for Research · Canton, United States
    • Mel A. Ona, M.D., Incorporated · Kapolei, United States
    • Central Illinois Diabetes and Clinical Research, a Division of Prairie Education and Research Cooper · Springfield, United States
    • Pinnacle Clinical Research Georgetown · Austin, United States
    • American Research Corporation · San Antonio, United States
    • Gastroenterology Clinic of San Antonio PA · San Antonio, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07575399
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 11, 2026
Primary completion
Jan 3, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion